Drugs / TETRAXIM™
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00319852 | Apr 2006 → Apr 2008 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01437423 | Jun 2011 → Nov 2015 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01031303 | Dec 2009 → Sep 2010 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01214889 Comparator | Sep 2010 → Nov 2011 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TETRAXIM | “TETRAXIM™: Diphtheria, Tetanus, Polio, Acellular Pertussis” NCT00319852 ↗ |
| Known as | DTacP-IPV | “sanofi pasteur's DTacP-IPV combined vaccine (TETRAXIM™) at 4 to 6 years of age” NCT01031303 ↗ |
| Modality | Vaccine | “The safety and immunogenicity of a tetravalent acellular pertussis combined vaccine” PMID 23077849 ↗ May 2012 |
| Route | Intramuscular | “0.5 mL, IM” NCT00319852 ↗ |